echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The latest research results of Zhou Binbing's research group at the Affiliated Children's Medical Center reveal: chemotherapeutic drugs can repair the lack of misalignment...

    The latest research results of Zhou Binbing's research group at the Affiliated Children's Medical Center reveal: chemotherapeutic drugs can repair the lack of misalignment...

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    As early as 2014, the Affiliated Children’s Medical Center and the St.
    Sud Children’s Research Hospital in the United States initiated the Chinese Pediatric Oncology Committee’s Emergency and Lymphatic Multi-Center Collaborative Group Program (CCCG-ALL-2015).
    The results showed that the 5-year overall survival rate was 91.
    1%.
    The event survival rate was 80.
    3%, and the curative effect reached the international advanced level

    .
    However, it is not clear how leukemia cells acquire drug-resistant gene mutations

    .
    At present, there are two mainstream views: 1.
    The drug-resistant gene mutations already exist in the form of tiny clones when cancer occurs, and they are enriched by drug screening during the chemotherapy process; 2.
    The drug-resistant gene mutations do not exist at the time of cancer.
    It is regained in the course of treatment

    .
    Among them, whether chemotherapy can directly induce drug-resistant mutations has been lack of relevant experimental evidence

    .

    July 22, 2021, National Children's Medical Center (Shanghai)/Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Zhou Binbing, Key Laboratory of Children's Hematological Tumors, National Health Commission The team, the Jinghui Zhang team of the St.
    Sude Children’s Research Hospital in the United States, and the Renate Kirschner-Schwabe team of the Charles University Hospital in Germany have published an online publication titled "Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse" in the international authoritative journal Nature Cancer.
    "The latest research results (https://doi.
    org/10.
    1038/s43018-021-00230-8)

    .

    This study provides the first direct genomics and cytology experimental evidence for ALL chemotherapy drugs to induce drug-resistant mutations, indicating that the chemotherapeutic drug mercaptopurine may directly induce drug-resistant gene mutations in patients with mismatch repair defects, making tumor cells resistant to a variety of Resistance to other chemotherapeutic drugs has led to the recurrence of leukemia
    .

    The study comprehensively analyzed samples of 1951 ALL patients from China, the United States, and Germany, and found that the tumor suppressor gene TP53 R248Q mutation was significantly enriched in relapsed ALL
    .
    This mutation will cause ALL cells to be resistant to multiple chemotherapeutic drugs, such as vincristine, daunorubicin, cytarabine and methotrexate

    .
    At the same time, the study used whole-genome sequencing to analyze paired samples from 181 childhood ALL patients with initial, remission and recurrence, and found for the first time the characteristic mercaptopurine mutation signature of relapsed ALL, which reflects the genetics of mercaptopurine-induced gene mutations during chemotherapy.
    The course of change

    .
    Further studies have found that mismatch repair defects significantly increase the rate of gene mutations induced by mercaptopurine, such as the tumor suppressor gene TP53 R248Q mutation

    .
    The study further reproduced the process of mercaptopurine directly inducing TP53 mutation and chemotherapy resistance in in vitro cell line experiments

    .

    The results of this study provide experimental evidence that chemotherapeutics may directly induce drug-resistant mutations
    .
    At the same time, it suggests that ALL patients with mismatch repair defects (about 8% of relapsed patients) will face a huge risk of mercaptopurine medication, and the treatment strategy should be changed
    .
    The research results suggest that in the future, monitoring the bone marrow during the treatment process, detecting related mutations as soon as possible to guide clinical medication, and screening high-risk patients who may be the beneficiaries of emerging therapies such as CAR-T
    are of positive significance for improving the accuracy of leukemia treatment
    .
    This work also has an important contribution to the clonal evolution mechanism of leukemia.
    It was
    found that some drug-resistant mutations were not pre-existed in small amounts at the initial onset, but were directly induced by chemotherapeutic drugs, which changed people's understanding and cognition of the source of drug-resistant mutations
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.